Last reviewed · How we verify
TOSITUMOMAB
At a glance
| Generic name | TOSITUMOMAB |
|---|---|
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2003 |
Approved indications
Common side effects
Key clinical trials
- S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma (PHASE3)
- Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma (PHASE2)
- Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma (PHASE1)
- Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma (PHASE2)
- Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma (PHASE1,PHASE2)
- A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma (PHASE2)
- Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) (PHASE3)
- Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TOSITUMOMAB CI brief — competitive landscape report
- TOSITUMOMAB updates RSS · CI watch RSS